miRNASNP-v3

miRNASNP-v3 provides a comprehensive database and analysis resource for investigating single-nucleotide polymorphisms (SNPs) and disease-related variations (DRVs) in microRNAs (miRNAs), their effects on pre-miRNA secondary structure, miRNA-target binding, and downstream gene regulation.

Key Features:

• Extensive Database Coverage: Compilation of 7,161,741 SNPs and 505,417 DRVs across 1,897 pre-miRNAs (maturing into 2,630 miRNAs) and the 3' untranslated regions (UTRs) of 18,152 genes.
• Disease Association Exploration: Cataloguing and exploration of associations between miRNA-related SNPs/DRVs and various diseases.
• miRNA-Target Binding Analysis: Analysis of how SNPs/DRVs affect miRNA interactions with target mRNAs.
• Functional Enrichment Analysis: Assessment of gain or loss of miRNA targets caused by genetic variations with downstream pathway and functional enrichment analysis.
• Drug Sensitivity Correlation: Investigation of correlations between drug sensitivity and miRNA expression.
• Cancer Expression Profiles: Examination of expression profiles of miRNAs and their targets across cancers.
• Pre-miRNA Structural Impact Analysis: Analysis of SNP/DRV effects on pre-miRNA secondary structure changes relevant to miRNA biogenesis.
• Custom Variation Prediction: Prediction of effects of user-defined variations on miRNA-target binding and pre-miRNA secondary structure.

Scientific Applications:

• Genetic Research: Screening and characterization of functional SNVs in miRNAs and their regulatory impacts on gene expression.
• Disease Mechanism Studies: Investigating how miRNA-related SNPs/DRVs contribute to disease pathogenesis and susceptibility.
• Pharmacogenomics: Correlating miRNA expression and genetic variation with drug sensitivity to inform pharmacogenomic studies.
• Cancer Research: Analyzing miRNA and target expression changes in cancer to identify biomarkers and candidate therapeutic targets.

Methodology:

Compilation of SNPs and DRVs across pre-miRNAs and 3' UTRs; analysis of SNP/DRV effects on miRNA-target binding and pre-miRNA secondary structure; functional enrichment analysis of gained or lost miRNA targets; correlation analysis between drug sensitivity and miRNA expression; querying miRNA and target expression profiles in cancers; prediction of effects for user-defined variations on binding and structure.